Bridgeway Capital Management’s Gyre Therapeutics GYRE Stock Holding History

Bridgeway Capital Management’s Portfolio GYRE Stock Details GYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-524	Closed	-$1.23M	–	1508
2015 Q1	$1.23M	Hold	524	–	–	0.03%	709
2014 Q4	$1.08M	Buy	524 +205	+64%	+$395K	0.02%	740
2014 Q3	$636K	Buy	319 +137	+75%	+$339K	0.02%	966
2014 Q2	$646K	Hold	182	–	–	0.02%	969
2014 Q1	$681K	Buy	182 +44	+32%	+$163K	0.02%	940
2013 Q4	$449K	Hold	138	–	–	0.01%	1091
2013 Q3	$575K	Buy	138 +2	+1%	+$8.05K	0.02%	960
2013 Q2	$456K	Buy	+136	New	+$517K	0.02%	988

Other funds holding GYRE

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

DCM

DG Capital Management New York $326M AUM 39.67% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Bridgeway Capital Management's GYRE Position: Q2 2015 in Review

Bridgeway Capital Management sold out of Gyre Therapeutics (GYRE) in Q2 2015, closing a stake of 524 shares — an estimated $1.23M sold.

Bridgeway Capital Management first reported a position in GYRE in Q2 2013 and held it in 8 quarters. The position peaked at $1.23M in Q1 2015. 46 funds tracked by Wall St. Rank hold GYRE as of Q2 2015.

Bridgeway Capital Management reported no remaining Gyre Therapeutics position as of Q2 2015 after selling out during the quarter.
Bridgeway Capital Management sold 524 Gyre Therapeutics shares in Q2 2015, an estimated $1.23M.
Bridgeway Capital Management first reported a position in Gyre Therapeutics in Q2 2013 and held it in 8 quarters.
Bridgeway Capital Management's Gyre Therapeutics position peaked at $1.23M in Q1 2015.
46 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q2 2015.

Based on Bridgeway Capital Management's 13F filing for Q2 2015, filed 14 Aug 2015.